X0306 4 2022-03-04 0 0001582313 Xenon Pharmaceuticals Inc. XENE 0001665430 EMPFIELD JAMES R. 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 BRITISH COLUMBIA, CANADA 0 1 0 0 EVP, Drug Discovery Common Shares 2022-03-04 4 M 0 25000 8.40 A 35000 D Common Shares 2022-03-04 4 F 0 6685 31.42 D 28315 D Common Shares 2022-03-04 4 S 0 18315 30.79 D 10000 D Common Shares 2022-03-07 4 M 0 2500 8.40 A 12500 D Common Shares 2022-03-07 4 F 0 695 30.23 D 11805 D Common Shares 2022-03-07 4 M 0 40000 6.76 A 51805 D Common Shares 2022-03-07 4 F 0 8952 30.23 D 42853 D Common Shares 2022-03-07 4 S 0 1805 30.62 D 41048 D Common Shares 2022-03-07 4 S 0 31048 30.54 D 10000 D Stock Option (Right to Buy) 8.40 2022-03-04 4 M 0 25000 0.00 D 2027-03-12 Common Shares 25000 0 D Stock Option (Right to Buy) 8.40 2022-03-07 4 M 0 2500 0.00 D 2027-03-12 Common Shares 2500 0 D Stock Option (Right to Buy) 6.76 2022-03-07 4 M 0 40000 0.00 D 2026-02-07 Common Shares 40000 0 D Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. /s/ Cassandra Robinson, Attorney-in-fact 2022-03-08